Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bevacizumab
Bevacizumabum
Bleomycin Sulphate
Carboplatin
Chlorambucilum
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxelum
Doxorubicinum
Doxorubicinum Liposomanum Pegylatum
Epirubicinum
Etoposidum
Fluorouracilum
Gemcitabine
Ifosfamidum
Irinotecanum
Melphalanum
Methotrexatum
Paclitaxel
Tamoxifenum
Topotecanum Inj.
Trabectedin
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- ovarian cancer
- endometrial cancer
- » TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.
- » A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)
- » A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
- » A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
- » Assessment of the Concentrations of Pro- and Anti-inflammatory Cytokines and Their Association With the Metabolic Profile of Women With PCOS